Canopy Growth Corporation (NASDAQ:CGC - Get Free Report) insider Christelle Gedeon sold 13,344 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $1.47, for a total transaction of $19,615.68. Following the transaction, the insider owned 692,162 shares in the company, valued at $1,017,478.14. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Christelle Gedeon also recently made the following trade(s):
- On Wednesday, June 17th, Christelle Gedeon sold 58,994 shares of Canopy Growth stock. The stock was sold at an average price of $0.97, for a total transaction of $57,224.18.
Canopy Growth Trading Up 1.9%
Shares of CGC opened at $1.07 on Wednesday. Canopy Growth Corporation has a fifty-two week low of $0.84 and a fifty-two week high of $2.38. The firm has a market cap of $480.75 million, a price-to-earnings ratio of -2.38 and a beta of 0.81. The firm has a 50 day moving average price of $0.96 and a 200-day moving average price of $1.03. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.39 and a current ratio of 3.04.
Canopy Growth (NASDAQ:CGC - Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $142.62 million for the quarter, compared to analyst estimates of $58.21 million. Canopy Growth had a negative net margin of 65.33% and a negative return on equity of 21.91%. As a group, equities research analysts forecast that Canopy Growth Corporation will post -0.1 earnings per share for the current year.
Institutional Trading of Canopy Growth
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its holdings in Canopy Growth by 1,115.6% in the first quarter. Royal Bank of Canada now owns 975,967 shares of the company's stock valued at $927,000 after acquiring an additional 895,680 shares in the last quarter. Lazard Asset Management LLC bought a new position in Canopy Growth in the 1st quarter worth $1,716,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Canopy Growth by 723.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,595,330 shares of the company's stock worth $5,239,000 after purchasing an additional 4,037,281 shares during the period. Virtu Financial LLC bought a new stake in shares of Canopy Growth during the 4th quarter valued at about $117,000. Finally, Mackenzie Financial Corp increased its position in shares of Canopy Growth by 173.0% during the fourth quarter. Mackenzie Financial Corp now owns 305,578 shares of the company's stock valued at $354,000 after buying an additional 193,633 shares during the period. Hedge funds and other institutional investors own 3.33% of the company's stock.
Analysts Set New Price Targets
CGC has been the subject of a number of recent research reports. Wall Street Zen raised Canopy Growth from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings downgraded Canopy Growth from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold".
Check Out Our Latest Research Report on CGC
Canopy Growth Company Profile
(
Get Free Report)
Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.
The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
